Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

14

Revenue 2017

Opdivo

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Opdivo was produced by Gilead Sciences.

Another blow for BMS in first-line NSCLC as it pulls EU filing

Another blow for BMS in first-line NSCLC as it pulls EU filing Opdivo/Yervoy combination is still under review with the FDA. Bristol-Myers Squibb has decided to abandon its marketing application in the EU for its Opdivo/Yervoy checkpoint inhibitor combination in ... trial, which evaluated Opdivo/Yervoy given

Roche files Tecentriq/Avastin combo in liver cancer

Roche files Tecentriq/Avastin combo in liver cancer Bristol-Myers Squibb’s Opdivo (nivolumab).

Newly-listed BioNTech buys Neon to boost cell therapy assets

Newly-listed BioNTech buys Neon to boost cell therapy assets who are not responding to treatment with checkpoint inhibitor drugs like Bristol-Myers Squibb’s Opdivo (nivolumab) and Merck &Co’s Keytruda (pembrolizumab).

FDA starts priority review of BMS Opdivo/Yervoy in first-line NSCLC

FDA starts priority review of BMS Opdivo/Yervoy in first-line NSCLC A verdict is expected to be delivered by 15 May. Bristol-Myers Squibb’s marathon to get approval for its immuno-oncology drug Opdivo in first-line non-small cell lung ... The FDA has started a priority review of PD-1 inhibitor Opdivo (nivolumab) in

Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer

Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer A combination trial of Rubraca plus Bristol-Myers Squibb’s checkpoint inhibitor Opdivo (nivolumab) – called CheckMate 9KD – is also ongoing with initial results due later this year.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

Keep your audiences close
How getting up close and personal with target audiences can fuel creativity...
The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....

Infographics